News | August 06, 2025
Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Cenexi reports an EBITDA breakeven for the quarter
Cenexi reports an EBITDA breakeven for the quarter
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
The product will be marketed by Dr. Reddy's
Granules now has a total of 67 ANDA approvals from the USFDA
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Subscribe To Our Newsletter & Stay Updated
